What is metastatic non-small cell lung cancer (NSCLC)?
Lung cancer is a cancer that starts in your lungs. There are 2 main types of lung cancer: NSCLC and small cell lung cancer. About 85% of people with lung cancer have NSCLC. Lung cancer may spread to other parts of the body, including bones, adrenal glands, the brain, and the liver. People with lung cancer whose cancer cells have spread to these places likely have metastatic cancer.
Metastatic NSCLC can be driven by a gene in your body. One of those genes is RET.
Talk to your doctor to see if your cancer is RET-positive.
Now Retevmo is available for RET-positive metastatic NSCLC
RET=rearranged during transfection.
Retevmo may help by targeting what is driving your RET-positive metastatic NSCLC
Retevmo was studied in the largest clinical trial of people with RET-positive cancers. The trial included 330 people with metastatic NSCLC, and 144 had tumors that were eligible to be evaluated for shrinkage. The trial evaluated how many people responded to treatment, which means their tumors either shrank or disappeared completely, and how long the response lasted.
Retevmo may affect both healthy cells and tumor cells, which can result in side effects, some of which can be serious.
Retevmo was shown to shrink tumors in the majority of people with RET-positive metastatic NSCLC
of the 39 people who had never received any cancer treatment had an objective response, meaning their tumors shrank by 30% or more
- Median* length of response has not yet been reached, as the trial is ongoing
of the 105 people who had prior cancer treatment† had an objective response
- Responses lasted a median* of 17.5 months
*Median is the middle number in a range of numbers.
In the trial, Retevmo reduced the size of tumors in the brain in people with metastatic RET-positive NSCLC who had prior cancer treatments†
people whose metastatic NSCLC had spread to their brain saw their brain tumors shrink by at least 30% or disappear completely
- All 10 people saw a response of 6 months or longer
†Platinum-based chemotherapy; some had also received other therapies.
SELECT SAFETY INFORMATION
Common side effects
The most common side effects of RETEVMO include:
- increased levels of liver enzymes
- increased blood sugar levels
- decrease in white blood cell count
- decreased protein levels (albumin) in the blood
- decreased levels of calcium in the blood
- dry mouth
- diarrhea
- increased creatinine (kidney function test)
- high blood pressure
- tiredness
- swelling of your arms, legs, hands, and feet (peripheral edema)
- decrease in platelet count
- increased cholesterol levels
- rash
- decreased levels of salt (sodium) in the blood
- constipation
RETEVMO may affect fertility in females and males, which may affect your ability to have children. Talk to your doctor if this is a concern for you.
These are not all the possible side effects with RETEVMO.
Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.
Learn how to take Retevmo.
Read more about what could be driving your cancer.